Hematology · Multiple MyelomaRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 6:31:44 AM

Assessment confidence: 89% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for REVLIMID is a significant regulatory milestone that could enhance its market position in treating multiple myeloma. This development necessitates close monitoring of the approval process and potential implications for market dynamics and competitive positioning. Regulatory context from FDA (FDA AP — REVLIMID (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (23 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the potential for expanded indications and market share for REVLIMID following this submission. The strongest clinical anchor is 18F-Fluciclovine PET/CT in Multiple Myeloma (ClinicalTrials.gov), sponsor/company relevance (bristol myers squibb). In Hematology · Multiple Myeloma, 5 regulatory and 6 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma (Bristol Myers Squibb) — entity match (bristol myers squibb). Secondary pressure from U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — REVLIMID (SUPPL) (FDA). Entity match (bristol myers squibb). Relevant agencies in corpus: FDA, PMDA. The acceptance of the supplemental application indicates a pathway for potential expanded indications, which could influence future labeling and compliance requirements.

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, REVLIMID could capture additional market share, impacting revenue streams for both Bristol Myers Squibb and its competitors in the multiple myeloma space.
Lead sponsor: AstraZeneca. This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Portfolio teams should evaluate the potential for expanded indications and market share for REVLIMID following this submission.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the review process and any subsequent approval timelines from the FDA.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — ELIQUIS (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
[IBENTO][IBENTO]PMDA-ATC Blood Products Seminar 2026 for PPWG Applications open.
PMDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

18F-Fluciclovine PET/CT in Multiple Myeloma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple My
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Study at Multiple Centers to Evaluate the Safety and Practicality of the Levita Magnetic Surgical System for Use in Laparoscopic Upper Gastrointestinal Surgeries.
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Care Transitions App for Patients With Multiple Chronic Conditions
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Global
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
FDA grants supplemental application approval for Dupixent (BLA761055)
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)

A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders.
PubMedhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
REVLIMID
competitors in hematology

Commercial impact

medium

If approved, REVLIMID could capture additional market share, impacting revenue streams for both Bristol Myers Squibb and its competitors in the multiple myeloma space.

Regulatory impact

medium

The acceptance of the supplemental application indicates a pathway for potential expanded indications, which could influence future labeling and compliance requirements.

What to watch

Monitor for updates on the review process and any subsequent approval timelines from the FDA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.